Skip to main content
. 2019 Dec 12;138(2):136–146. doi: 10.1001/jamaophthalmol.2019.5132

Table 2. Clinical Outcomes.

Clinical Outcomes Group, No. (%) Difference, Mean (95% CI) P Value
Bevacizumab (n = 1131) Control (n = 117)
Follow-up time, mo
Mean 40 58 −18 (−24 to −13) <.001a
Median (range) 34 (3 to 117) 61 (3 to 130)
Enucleation 15 (1) 3 (3) NA .44
Snellen visual acuity
No. 1116 114 NA .002a
20/20 to 20/40 419 (37) 31 (27)
20/50 to 20/150 299 (27) 24 (21)
20/200 or worse 398 (36) 59 (52)
Visual acuity (Snellen)
Median 20/70 20/200 NA NA
Mean (range) 20/200 (20/20 to NLP) CF (20/20 to NLP)
Visual acuity (logMAR)
Median 0.54 1.30 −0.49 (−0.71 to −021) <.001a,b
Mean (range) 1.02 (0.00 to 5.00) 1.53 (0.00 to 5.00)
Lines of visual acuity loss at last follow-up date
Median 2 5 −1 (−2 to 0) .01a,b
Mean (range) 4 (0 to 14) 5 (0 to 14)
Tumor features
Tumor basal diameter, mm
Mean 10.5 9.9 0.7 (−0.1 to 1.4) .09
Median (range) 10.0 (1.0 to 20.0) 10.0 (2.0 to 20.0)
Tumor thickness, mm
Mean 2.6 2.5 0.2 (−0.1 to 0.5) .23
Median (range) 2.2 (0.5 to 12.0) 2.0 (1.0 to 9.8)
Recurrence of tumor 23 (2) 5 (4) NA .18
Time to recurrence, mo
Mean 28 62 −34 (−55 to −14) .01a
Median (range) 20 (4 to 80) 67 (27 to 92)
Radiation complications
Cystoid macular edema by OCT 413 (37) 58 (50) NA .01a
Time to onset of cystoid macular edema, mo
Mean 27 27 0 (−6 to 5) .84
Median (range) 22 (3 to 98) 20 (3 to 104)
Radiation maculopathy 431 (38) 59 (50) NA .01a
Time to radiation maculopathy, mo
Mean 29 27 1 (−3 to 6) .58
Median (range) 24 (4 to 114) 20 (4 to 68)
Radiation papillopathy 197 (17) 31 (27) NA .02a
Time to radiation papillopathy, mo
Mean 30 27 2 (−4 to 8) .47
Median (range) 27 (2 to 93) 21 (4 to 72)
Nonproliferative radiation retinopathy 269 (24) 40 (34) NA .01a
Time to nonproliferative radiation retinopathy, mo
Mean 28 27 0 (−5 to 6) .88
Median (range) 24 (4 to 97) 21 (4 to 72)
Proliferative radiation retinopathy 7 (1) 7 (6) NA <.001a
Time to proliferative radiation retinopathy, mo
Mean 33 35 −1 (−25 to 22) .92
Median (range) 36 (3 to 55) 26 (11 to 72)
Retinal vessel occlusion
Branch retinal vein occlusion 310 (27) 42 (36) NA .43
Central retinal vein occlusion 7 (1) 0
Branch retinal artery occlusion 8 (1) 0
Time to retinal vessel occlusion, mo
Mean 27 33 −6 (−12 to 0) .07
Median (range) 23 (3 to 103) 35 (4 to 88)
Neovascularization of the iris 31 (3) 7 (6) NA .05
Time to neovascularization of the iris, mo
Mean 33 29 4 (−13 to 21) .66
Median (range) 33 (4 to 69) 22 (11 to 75)
Neovascular glaucoma 32 (3) 7 (6) NA .06
Time to neovascular glaucoma, mo
Mean 38 33 5 (−15 to 25) .63
Median (range) 34 (4 to 96) 22 (11 to 86)
Cataract 302 (27) 45 (38) NA .01a
Time to cataract, mo
Mean 27 27 −1 (−7 to 6) .81
Median (range) 21 (2 to 138) 24 (2 to 79)
Scleral necrosis 12 (1) 3 (3) NA .39
Time to scleral necrosis, mo
Mean 40 34 5 (−23 to 34) .70
Median (range) 35 (8 to 81) 33 (10 to 60)

Abbreviations: CF, counting fingers; NLP, no light perception; NA, not applicable; OCT, optical coherence tomography.

a

Significant P value

b

By Mann-Whitney U test.